Gough Peter J, Garton Kyle J, Wille Paul T, Rychlewski Marcin, Dempsey Peter J, Raines Elaine W
Department of Pathology, University of Washington, Harborview Medical Center, Seattle, WA 98104, USA.
J Immunol. 2004 Mar 15;172(6):3678-85. doi: 10.4049/jimmunol.172.6.3678.
CXC chemokine ligand (CXCL)16 and scavenger receptor for phosphatidylserine and oxidized low-density lipoprotein were independently identified as a chemokine and a scavenger receptor, respectively, but have since been shown to be identical. CXCL16 is synthesized as a transmembrane protein with its chemokine domain at the end of a mucin-rich stalk. When expressed at the cell surface, CXCL16 functions as a scavenger receptor, binding and internalizing oxidized low-density lipoprotein and bacteria. As a soluble form, CXCL16 is a chemoattractant for activated CD4+ and CD8+ T cells through binding its receptor, CXCR6. In this study, we examined the mechanisms that regulate the conversion between these two functionally distinct forms of CXCL16. We demonstrate that murine CXCL16 is synthesized as an intracellular precursor that is rapidly transported to the cell surface where it undergoes metalloproteinase-dependent cleavage, causing the release of a fragment that constitutes the majority of the CXCL16 extracellular domain. Using a novel retroviral system for the generation of short interfering RNAs, we show that knockdown of a disintegrin and metalloproteinase (ADAM) family protease ADAM10 decreases this constitutive shedding of CXCL16. Furthermore, we show that overexpression of ADAM10 increases CXCL16 shedding, whereas overexpression of a dominant-negative form of ADAM10 lowers shedding of CXCL16 in a similar manner to short interfering RNAs. Through the modulation of ADAM10 function, we demonstrate that ADAM10-mediated constitutive shedding is a key regulator of CXCL16 cell surface expression. The identification of ADAM10 as a major protease responsible for the conversion of CXCL16 from a membrane-bound scavenger receptor to a soluble chemoattractant will provide new information for understanding the physiological function of this molecule.
CXC趋化因子配体(CXCL)16和磷脂酰丝氨酸及氧化型低密度脂蛋白的清道夫受体最初分别被鉴定为一种趋化因子和一种清道夫受体,但后来发现它们是同一物质。CXCL16作为一种跨膜蛋白合成,其趋化因子结构域位于富含粘蛋白的茎的末端。当在细胞表面表达时,CXCL16作为清道夫受体发挥作用,结合并内化氧化型低密度脂蛋白和细菌。作为一种可溶性形式,CXCL16通过结合其受体CXCR6,对活化的CD4+和CD8+ T细胞具有趋化作用。在本研究中,我们研究了调节CXCL16这两种功能不同形式之间转换的机制。我们证明,小鼠CXCL16作为一种细胞内前体合成,该前体迅速转运到细胞表面,在那里它经历金属蛋白酶依赖性切割,导致释放出一个构成CXCL16细胞外结构域大部分的片段。使用一种用于生成短发夹RNA的新型逆转录病毒系统,我们发现抑制解整合素和金属蛋白酶(ADAM)家族蛋白酶ADAM10可减少CXCL16的这种组成性脱落。此外,我们表明ADAM10的过表达增加CXCL16的脱落,而ADAM10显性负性形式的过表达以与短发夹RNA类似的方式降低CXCL16的脱落。通过调节ADAM10的功能,我们证明ADAM10介导的组成性脱落是CXCL16细胞表面表达的关键调节因子。将ADAM10鉴定为负责将CXCL16从膜结合清道夫受体转化为可溶性趋化因子的主要蛋白酶,将为理解该分子的生理功能提供新的信息。